This is the login panel

  • Return to More On Orthopaedic Medicine > Individual Prolotherapy Study Summaries > Achilles Tendinosis

    Dextrose prolotherapy versus eccentric loading exercises or a combination for Achilles tendinosis. Yelland et al (2009)

    Yelland MJ, Sweeting KR, Lyftogt JA, Ng SK, Scuffham PA, Evans KA. Prolotherapy injections and eccentric loading exercises for painful Achilles tendinosis: a randomised trial [epub ahead of print] Br J Sports Med (England), Jun 22 2009, pages pending.

    This study also used the VISA-A. This study was a superior design to Vos et al because there was an exercise only group as the control. In addition there was an injection only group that did not exercise. It is important to note that eccentric lengthening exercises (ELE), the exercise approach used, is not a placebo intervention, and is commonly used in the sports medicine community. ELE is particularly effective in mid portion Achilles tendinopathy which these patients had. The injection group was not an intratendinous injection but rather involved simple subcutaneous injection of dextrose without radiographic guidance. Injections were repeated weekly in the injection group. Thus this study was a treatment comparison study of usual treatment (ELE) versus injection treatment versus combined exercise and injection. It is of interest that reduction of stiffness and limitation of activity was faster with dextrose injection, and that combining both eccentric loading and dextrose injection combined was significantly better than eccentric activity alone. A larger study will be of much interest if funding is available.

    An abstract of dextrose prolotherapy versus eccentric loading exercises is available here, with a copy of the content below.

    OBJECTIVE: To compare the effectiveness and cost-effectiveness of eccentric loading exercises (ELE) with prolotherapy injections used singly and in combination for painful Achilles tendinosis.

    DESIGN: A single-blinded randomised clinical trial. The primary outcome measure was the VISA-A questionnaire with a minimum clinically important change (MCIC) of 20 points on a 100 point scale.

    SETTING: Five Australian private primary care centres.

    PARTICIPANTS: 43 patients with painful mid-portion Achilles tendinosis commenced and 40 completed the treatment protocols.

    INTERVENTIONS: Participants were randomised to a 12 week program of ELE (n=15), or prolotherapy injections of hypertonic glucose with lignocaine alongside the affected tendon (n=14) or combined treatment (n=14). Main outcome measurements: VISA-A, pain, stiffness and limitation of activity scores and treatment costs were assessed prospectively over 12 months.

    RESULTS: At 12 months, the proportions of participants achieving the MCIC for VISA-A scores were 73% for ELE, 79% for prolotherapy and 86% for combined treatment. Mean (95% CI) increases in VISA-A scores at 12 months were 23.7 (15.6 to 31.9) for ELE, 27.5 (12.8 to 42.2) for prolotherapy and 41.1 (29.3 to 52.9) for combined treatment. At 6 weeks and 12 months, these increases were significantly less for ELE than for combined treatment. Compared with ELE, reductions in stiffness and limitation of activity occurred earlier with prolotherapy and reductions in pain, stiffness and limitation of activity occurred earlier with combined treatment. Combined treatment had the lowest incremental cost per additional responder (AU$1539) compared with ELE.

    CONCLUSIONS: For Achilles tendinosis, prolotherapy and particularly ELE combined with prolotherapy give more rapid improvements in symptoms than ELE alone but long term VISA-A scores are similar.